Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

Disease-modifying data convinced Boehringer Ingelheim Venture Fund to co-lead the seed round for U.K. stem cell hearing loss company Rinri

Seven years after its first foray into hearing loss, Boehringer Ingelheim Venture Fund is investing in U.K. stem cell therapy company Rinri.

On May 20, Boehringer's corporate venture fund co-led a £1.4 million ($1.8 million) seed

Read the full 352 word article

How to gain access

Continue reading with a
two-week free trial.